Table 4 Surrogate and clinical responses... | American Society of Hematology

Table 4

Surrogate and clinical responses to imatinib

Patient no.	Response (last follow-up)	Prednisone, mg/d		Lee symptom score		Imatinib (mg/day) at last follow-up	Duration of therapy, wk
Patient no.	Response (last follow-up)	Baseline	Last follow-up	Baseline	Last follow-up	Imatinib (mg/day) at last follow-up	Duration of therapy, wk
1	Stable disease	15	0	10	9	400	72
2	Minor	5	15	28	4	400	25
3	Progressive disease	20	25	31	30	400	19.1
4	Minor	25	5	29	37	300	38.1
6	Major	40	7.5	11	2	200	75.7
7	Minor	20	0	73	22	400	79.7
8	Major	17.5	15	21	3	400	72
10	Stable disease	30	10	29	16	200	55.4
11	Progressive disease	5	30	29	37	200	56.6
12	Major	15	7.5	31	28	200	31.6
15	Stable disease	15	12.5	20	19	400	53.1

Patient no.	Response (last follow-up)	Prednisone, mg/d		Lee symptom score		Imatinib (mg/day) at last follow-up	Duration of therapy, wk
Patient no.	Response (last follow-up)	Baseline	Last follow-up	Baseline	Last follow-up	Imatinib (mg/day) at last follow-up	Duration of therapy, wk
1	Stable disease	15	0	10	9	400	72
2	Minor	5	15	28	4	400	25
3	Progressive disease	20	25	31	30	400	19.1
4	Minor	25	5	29	37	300	38.1
6	Major	40	7.5	11	2	200	75.7
7	Minor	20	0	73	22	400	79.7
8	Major	17.5	15	21	3	400	72
10	Stable disease	30	10	29	16	200	55.4
11	Progressive disease	5	30	29	37	200	56.6
12	Major	15	7.5	31	28	200	31.6
15	Stable disease	15	12.5	20	19	400	53.1

Patients 5, 9, 13, and 14 were not evaluable for clinical response.